We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Biliary Tract Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04578444
Expanded Access Status : Available
First Posted : October 8, 2020
Last Update Posted : November 10, 2022
Information provided by (Responsible Party):
Zymeworks Inc.

Tracking Information
First Submitted Date September 30, 2020
First Posted Date October 8, 2020
Last Update Posted Date November 10, 2022
Descriptive Information
Brief Title An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Biliary Tract Cancer
Brief Summary This is an intermediate-size Expanded Access Protocol (EAP) for use of zanidatamab (ZW25) in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced biliary tract cancer (BTC) who are not eligible for other zanidatamab clinical trials, and who in the opinion of the treating oncologist, would potentially benefit from treatment with zanidatamab.
Detailed Description Not Provided
Study Type Expanded Access
Expanded Access Type Intermediate-size Population
Intervention Drug: Zanidatamab
Administered intravenously
Other Name: ZW25
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Recruitment Information
Expanded Access Status Available
Contact: Zymeworks Clinical Trial Resource (206)-237-1030 medinfo@zymeworks.com
Contact: Early Access Care 203-441-7938 Zymeworks.EAP@earlyaccesscare.com
Listed Location Countries Not Provided
Removed Location Countries  
Administrative Information
NCT Number NCT04578444
Current Responsible Party Zymeworks Inc.
Original Responsible Party Same as current
Current Study Sponsor Zymeworks Inc.
Original Study Sponsor Same as current
Collaborators Not Provided
Investigators Not Provided
PRS Account Zymeworks Inc.
Verification Date November 2022